LightForce Orthodontics Secures $80 Million Series D Funding Led By Ally Bridge Group, Opens Second Digital Factory
LightForce Orthodontics will expand its manufacturing capabilities to advance production and further its custom orthodontic…
News
SnapLogic First to Market with the World’s Only Generative Integration Solution
SnapGPT now publicly available to help enterprises go faster, further and be more efficient SAN…
PPG inaugurates center of excellence in Italy that increases efficiency for automotive color development
Innovative facility combines color development and application; uses AI tools QUATTORDIO, Italy–(BUSINESS WIRE)–PPG (NYSE: PPG)…
Tachyum Demonstrates Support for Xen Hypervisor
LAS VEGAS–(BUSINESS WIRE)–#Linux—Tachyum® today announced that it has completed porting of all the software necessary…
Syneos Health Stockholders Approve Agreement with Private Investment Consortium
MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health”…
Syneos Health Stockholders Approve Agreement with Private Investment Consortium
MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health”…
Yield10 Bioscience Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina, Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market
–Findings demonstrate a key advancement in the development of proprietary Camelina varieties tolerant to application…
Yield10 Bioscience Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina, Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market
–Findings demonstrate a key advancement in the development of proprietary Camelina varieties tolerant to application…
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical…
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical…
RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update
— Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET —…
RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update
— Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET —…
Aridis Pharmaceuticals Announces $2 Million Offering
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (OTC: ARDS), a…
Aridis Pharmaceuticals Announces $2 Million Offering
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (OTC: ARDS), a…
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the…
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the…
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company)…
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company)…
First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema
LEOPARD trial initiation follows recent positive data from OCS-01 eye drops from the Stage 1…
First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema
LEOPARD trial initiation follows recent positive data from OCS-01 eye drops from the Stage 1…